secwatch / observer
8-K filed May 5, 2023, 7:59 PM ET ticker CLB CIK 0001958086
debt confidence high sentiment neutral materiality 0.55

Core Laboratories Inc. /DE/ (CLB): debt financing — Core Labs issues $50M in senior secured notes at 7.25%-7.50% to refinance debt

Core Laboratories Inc. /DE/

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

Core Laboratories Inc. /DE/ incurred senior notes of $50 million in aggregate principal amount with purchasers of the Notes at 7.25% and 7.50% maturing 2028 and 2030.

Instrument
senior notes
Principal
$50 million in aggregate principal amount
Counterparty
purchasers of the Notes
Rate
7.25% and 7.50%
Maturity
2028 and 2030
Event
incurrence
Exact text from the filing
On May 4, 2023, Core Laboratories Inc. (the “Company”) and Core Laboratories (U.S.) Interests Holdings, Inc. (the “Issuer”) completed a private placement of $50 million in aggregate principal amount of the Issuer’s senior secured notes with $25 million due 2028 (the “2028 Notes”) at an interest rate of 7.25% and $25 million due 2030 (the “2030 Notes”) at an interest rate of 7.50%.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Core Laboratories Inc. /DE/ entered into Note Purchase Agreement with the purchasers of the Notes valued at $50 million (effective 2023-05-04).

Action
entry
Agreement
notes offering
Counterparty
the purchasers of the Notes
Value
$50 million
Effective
2023-05-04
Exact text from the filing
The terms of the Notes are governed by a Note Purchase Agreement dated May 4, 2023 (the “Agreement”), between the Company, the Issuer and the purchasers of the Notes.
View on SEC.gov

Browse all debt financings →

Core Laboratories Inc. /DE/ filing history →

Source: SEC EDGAR
accession 0000950170-23-018053
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.